BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
Cannabis products with high levels of the psychedelic element found in marijuana – tetrahydrocannabinol, or THC — may be associated with improvements in chronic pain, according to a study published this month on the Annals of Internal Medicine.
Researchers examined ratios between THC and cannabidiol, or CBD, and found that synthetic, oral products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios “may be associated with short-term improvements in chronic pain,” according to the study.
The study, which examined outcomes of 18 randomized, placebo-controlled trials and seven cohort studies, also found that such products also hold an increased risk for dizziness and sedation.
Researchers pointed out that studies “are needed on long-term outcomes and further evaluation of product formulation effects.”